The data on Pfizer's GLP-1 offer early evidence that the injection can be administered less frequently than existing drugs ...
Eli Lilly and Novo Nordisk may want to enjoy their duopoly while they can.
Pfizer made one thing clear this week: It's officially back in the obesity race.
Considerable on MSN
Lilly’s Zepbound seen beating Pfizer injection
Eli Lilly’s Zepbound is still viewed as the leading weight-loss shot, according to a ...
Pfizer reported that its ultra-long-acting, once-monthly GLP-1 injectable achieved up to 12.3% placebo-adjusted weight loss ...
Pfizer's long-acting GLP-1 weight loss candidate could set the stage for a stock rally.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results